Conexeu Sciences (CNXU) Registration filing summary

Company overview and business model

• Focuses on developing a patented, temperature-responsive collagen-based ECM scaffold (CXU™) for regenerative tissue applications in wound care, aesthetics, dentistry, veterinary medicine, and 3D bioprinting.

• Originated from over a decade of academic research at the University of British Columbia, with exclusive global patent rights acquired in 2025.

• CXU™ is in preclinical development, designed to transition from liquid to gel in situ, supporting tissue integration and healing.

• Business model targets staged regulatory clearance, initial commercialization in wound care, and expansion into cash-pay markets like aesthetics and dentistry.

• Holds patents in the US, EU, Japan, and Australia, with additional filings pending in Canada.

Financial performance and metrics

• No revenues generated to date; company remains in pre-commercial, development stage.

• Net loss of $1.72 million for the three months ended January 31, 2026, up from $0.29 million in the prior year period, reflecting increased R&D and business development.

• Net loss for the fiscal year ended October 31, 2025 was $3.92 million, compared to $0.47 million in 2024.

• Cash and cash equivalents as of January 31, 2026 were $6.26 million, with working capital of $6.58 million.

• Raised over $10.1 million in equity since November 2024, including private placements and a $5 million Regulation Crowdfunding round.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by registered securityholders; proceeds from warrant exercises (up to $1.67 million) will be used for operations.

• Capital allocated to regulatory submissions, manufacturing scale-up, pilot programs, and R&D for FDA 510(k) submission and commercialization.

• Near-term capital needs include $1.62 million for FDA submission, $250,000 for manufacturing scale-up, and $225,000 for market entry and pilot programs.